(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 15.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Mannkind's revenue in 2026 is $348,966,000.On average, 11 Wall Street analysts forecast MNKD's revenue for 2026 to be $146,014,957,207, with the lowest MNKD revenue forecast at $133,348,948,407, and the highest MNKD revenue forecast at $154,734,199,461. On average, 11 Wall Street analysts forecast MNKD's revenue for 2027 to be $163,373,335,603, with the lowest MNKD revenue forecast at $114,215,911,517, and the highest MNKD revenue forecast at $189,728,246,641.
In 2028, MNKD is forecast to generate $166,824,060,452 in revenue, with the lowest revenue forecast at $114,311,422,652 and the highest revenue forecast at $228,148,370,637.